# Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours

> **NCT02941523** · PHASE1,PHASE2 · COMPLETED · sponsor: **Noxopharm Limited** · enrollment: 19 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** NOX66
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02941523
- **Lead sponsor:** Noxopharm Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-03
- **Primary completion:** 2018-12-31
- **Final completion:** 2019-01-10
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2021-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02941523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02941523, "Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02941523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*